Meta-[i]iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage

Nuclear Medicine Communications

Volumn 25, Issue 11, 2004, Pages 1125-1130

  He, Ying ^a   Das, Bikul ^a   Baruchel, Sylvain ^a   Kumar, Piyush ^a   Wiebe, Leonard ^a   Reilly, Raymond M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Auger electrons; Bone marrow stem cells; HL 60 cells; Neuroblastoma; SK N BE(2) cells; SK N SH cells

Indexed keywords

(3 IODOBENZYL)GUANIDINE; RADIOPHARMACEUTICAL AGENT; (3 IODOBENZYL)GUANIDINE I 123; 3 TRIMETHYLSILYLBENZYLGUANIDINE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL; HUMAN; NEUROBLASTOMA; PATHOLOGY; RADIATION EXPOSURE; RADIATION RESPONSE; TREATMENT OUTCOME; TUMOR CELL LINE; BONE MARROW TOXICITY; CANCER INHIBITION; CLONOGENIC ASSAY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GROWTH INHIBITION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN CELL; IC 50; LEUKEMIA CELL; NEUROBLASTOMA CELL; RADIOISOTOPE THERAPY;

3-IODOBENZYLGUANIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEMATOPOIETIC STEM CELLS; HUMANS; NEUROBLASTOMA; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 8444249642     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200411000-00010     Document Type: Article

References (23)

1. 131I-MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999; 32:427-431.
2. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16:229-236.
3. Rutgers M, Tytgat GAM, Verwus-Janssen M, Buttenhuis C, Voute PA, Smets LA. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and seretonin by human platelets and neuro-adrenergic tumour cells. Int J Cancer 1993; 54:290-295.
4. Gelfand MJ. Meta-iodobenzylguanidine in children. Semin Nucl Med 1993; 23:231-242.
5. O'Donoghue JA, Bardies M, Wheldon TE. Relationship between tumour size and curability for targeted radionuclide therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
6. Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998; 77:2061-2068.
7. Dose-response relationships for normal tissues. In: Hall EJ (editor). Radiobiology for the Radiologist, 4th edition. Philadelphia: JB Lippincott; 1994, pp. 45-74.
8. Hoefnagel CA, Smets LA, Voute PA, de Kraku J. Iodine-125-MIBG therapy for neuroblastoma. J Nucl Med 1992; 32:361-362.
9. 131I-meta-iodobenzylguanidine: Comparison of production from meta-diazobenzylguanidine and from metatrimethylsilylbenzylguanidine. Nucl Med Commun 1994; 15:268-274.
10. Wieland DM, Wu J, Brown LE, Manger TJ, Swanson DP, Beirwaltes WH. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with I-131 iodobenzylguanidine. J Nucl Med 1980; 21:349-353.
11. Das B, Yeger H, Baruchel H, Freedman MH, Koren G, Baruchel S. In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity: implications in cancer chemotherapy. Eur J Cancer 2003; 17:2556-2565.
12. Ellis WM, Georgiou GM, Roberton DM, Johnson GR. The use of discontinuous Percoll gradients to separate populations of cells from human bone marrow and peripheral blood. J Immunol Methods 1984; 66:9-16.
13. Sutherland H, Eaves A, Eaves C. Quantitative Assays for Human Hemopoietic Progenitor Cells. Boca Raton, FL: CRC Press; 1991.
14. Eaves C, Lambi K. Atlas of Human Hematopoietic Colonies. Vancouver: Stem Cell Technologies Inc.; 1995.
15. Mairs RJ, Cunningham SH, Russell J, Armour A, Owens J, McKellar K, et al. No-carrier-added iodine-131-MIBG: Evaluation of a therapeutic preparation. J Nucl Med 1995; 36:1088-1095.
16. Smets LA, Bout B, Wisse J. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG). Cancer Chemother Pharmacol 1988; 21:9-13.
17. Loesberg C, Van Rooij H, Nooijen WJ, Meijer AJ, Smets LA. Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG). Int J Cancer 1990; 46:276-281.
18. Malmquist J, Oates JA. Effects of adrenergic neuron-blocking guanidine derivatives on mitochondrial metabolism. Biochem Pharmacol 1968; 17:1845-1854.
19. 131I-MIBG. J Nucl Med 2001; 42:1713-1721.
20. Sisson JC, Hutchinson RJ, Shapiro B, Zasadny KR, Normolle D, Wieland DM, et al. Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med 1990; 31:1479-1485.
21. Sisson JC, Shapiro B, Hutchinson RJ, Carey JE, Zasadny KR, Zempel SA, et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med 1994; 21:46-52.
22. 125I-MIBG. Am J Clin Oncol 1996; 19:144-148.
23. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996; 41:1871-1884.